Methotrexate
| Drug Category | Drug | IHD Dosing |
Administration Timing Around HD Session |
|---|---|---|---|
| Immunosuppressants | Methotrexate | Not recommended | Administer Post-HD |
|
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 454 | 85-100 | 8-12 | N/A | 50 | 0.4-0.8 | 92.1 | 63 (high flux) |
References:
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00563
- Wall S, Johansen M, Molony D, DuBose T, Jaffe N, Madden T. Effective clearance of methotrexate using high-flux hemodialysis membranes. American journal of kidney diseases (the official journal of the National Kidney Foundation) 1996; 28(6), 846-54.